Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1521-1532

  Miller, Veronica ^a   Phillips, Andrew ^d   Rottmann, Carsten ^d   Staszewski, Schlomo ^d   Pauwels, Rudi ^d   Hertogs, Kurt ^d   De Béthune, Marie Pierre ^d   Kemp, Sharon D ^b   Bloor, Stuart ^b   Harrigan, P Richard ^c   Larder, Brendan A ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Virco UK Ltd   (United Kingdom)

^c BC Center for Excellence in HIV/AIDS   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 17344367914     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515304     Document Type: Article

References (16)

1. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
2. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996;276:118-25.
3. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996;276:111-7.
4. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996;125:161-72.
5. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:477-83.
6. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimes from patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
7. 3 [LB7]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997:207.
8. Harris M, Durakovic C, Conway B, et al. A pilot study on indinavir, nevirapine, and 3TC in patients with advanced HIV disease [abstract 234]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997:107.
9. Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA. Generation of drug-resistant variants of human immunodeficiency virus type I by in vitro passage in increasing concentrations of 2′, 3′-dideoxycytidine and 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:130-3.
10. Boucher CAB, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
11. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
12. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
13. Wainberg MA, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995;9:351-7.
14. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
15. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1115-58.
16. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.